DALLAS, October 4, 2014 /PRNewswire/ --
ReportsnReports.com adds Global Pancreatic Cancer Market 2014-2018 and Pancreatic Cancer - Pipeline Review, H1 2014 research reports to the pharmaceuticals section of its industry intelligence library. Spread across 97 pages and 956 pages respectively, these reports can be ordered for US$ 2500 each (single user PDF) with ReportsnReports.com at http://www.reportsnreports.com/reports/300141-global-pancreatic-cancer-market-2014-2018.html and http://www.reportsnreports.com/reports/286751-pancreatic-cancer-pipeline-review-h1-2014.html .
The Global Pancreatic Cancer Market 2014-2018 research report says based on the initiation, pancreatic cancer can be classified into exocrine pancreatic cancer and endocrine pancreatic cancer. When pancreatic cancer cells spread from the pancreas to other parts of the body, it is known as metastatic pancreatic order. The incidence and mortality rate of pancreatic cancer is higher in men than in women. SEER estimates that there were 46,420 new pancreatic cancer cases recorded in the US in 2014. It also estimated that 39,590 deaths occurred in the US in 2014 as a result of pancreatic cancer, accounting for 6.8 percent of the total cancer deaths in the US. The report also presents the vendor landscape and a corresponding detailed analysis of the vendors in the Global Pancreatic Cancer market. In addition, it discusses the major drivers that influence the growth of the market and outlines the challenges faced by the vendors. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat different types of pancreatic cancer.
Companies discussed in this 2014-2018 pancreatic cancer industry report include Celgene, Eli Lilly, F. Hoffmann-La Roche, Novartis, PFizer, AbGenomics International, AB Science, Aduro Biotech, Aphios, Celsion, Gilead Sciences, Halozyme Therapeutics, Merrimack Pharmaceuticals, Momenta Pharmaceuticals, OncoMed Pharmaceuticals, Oncozyme Pharma, Ostuka Holdings, Rexahn Pharmaceuticas and Zeria Pharmaceutica. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=300141 .
The Pancreatic Cancer Pipeline Review, H1 2014 report provides an overview of the Pancreatic Cancer's therapeutic pipeline. It provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of this H1 2014 pipeline review report on pancreatic cancer covers: The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer; The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects; The report summarizes all the dormant and discontinued pipeline projects; A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type and Latest news and deals relating related to pipeline products. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=286751 .
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@reportsandreports.com
Connect With Us on:
Facebook: https: //http://www.facebook.com/pages/ReportsnReports/191441427571689
LinkedIn: http://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/
RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml
